triple negative breast cancer

[Gilead Sciences, Inc.] Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Trodelvy® as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic TNBC who have received two or more prior systemic therapies.

[CytoDyn, Inc.] CytoDyn, Inc. announced that Health Canada authorized the emergency use of leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, for the treatment of a patient with metastatic triple-negative breast cancer.

[Scientific Reports] Scientists used mammary tumors with in situ immunomodulation consisting of intratumoral injections of Flt3L to mobilize conventional type-1 dendritic cells (cDC1s), local irradiation to induce immunogenic tumor cell death, and TLR3/CD40 stimulation to activate cDC1s.

[Scientific Reports] Breast cancer cells preferentially metastasize to bone. To study the bone-tumor paracrine influence, a tri-cellular 3-D vascularized breast cancer tissue model was engineered which comprised MDA-MB231, TNBCs, fibroblasts, and endothelial cells.

[Communications Biology] Investigators showed that high expression of dihydrolipoamide S-succinyltransferase (DLST), a tricarboxylic acid (TCA) cycle enzyme, predicted poor overall and recurrence-free survival among TNBC patients.

[Nature Reviews Clinical Oncology] Scientists describe the current and upcoming therapeutic landscape of TNBC and discuss how an integrated view of the TNBC ecosystem can define different levels of risk and provide improved opportunities for tailoring treatment.